Xilio Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
XLO$8.53-5.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEM ENTS OF CASH FLOWS
(In thousands)
| Year Ended December 31, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $ | (35,036) | $ | (58,241) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization | 1,541 | 1,644 | ||
| Stock-based compensation expense | 6,939 | 6,434 | ||
| Change in fair value of common stock warrant liabilities | (5,845) | — | ||
| Issuance costs allocated to common stock warrant liabilities | 2,284 | — | ||
| Loss on disposal of property and equipment | — | 3 | ||
| Changes in operating assets and liabilities: | ||||
| Collaboration and license agreement receivable | (5,000) | — | ||
| Prepaid and other assets | 3,075 | (981) | ||
| Accounts payable | 152 | 1,526 | ||
| Accrued expenses and other liabilities | (979) | (1,543) | ||
| Deferred revenue | 27,877 | 32,780 | ||
| Net cash used in operating activities | (4,992) | (18,378) | ||
| Cash flows from investing activities: | ||||
| Purchases of property and equipment | (518) | (36) | ||
| Net cash used in investing activities | (518) | (36) | ||
| Cash flows from financing activities: | ||||
| Proceeds from issuance of prefunded warrants and common stock warrants in connection with a follow-on offering, net of issuance costs | 47,033 | — | ||
| Proceeds from issuance of common stock, prefunded warrants and liabilities to issue common stock in connection with the exercise of Series B warrants, net of issuance costs | 35,828 | — | ||
| Proceeds from issuance of common stock in connection with the exercise of prefunded warrants | 1 | — | ||
| Proceeds from issuance of common stock in connection with the AbbVie stock purchase agreement, net of issuance costs | 2,810 | — | ||
| Proceeds from issuance of common stock in connection with at-the-market offerings, net of issuance costs | 2,017 | 6,825 | ||
| Proceeds from issuance of common stock under employee stock purchase plan | 76 | 68 | ||
| Proceeds from exercise of stock options | 10 | 5 | ||
| Proceeds from issuance of common stock and prefunded warrants to Gilead and certain accredited investors in private placements, net of issuance costs | — | 25,680 | ||
| Repayments of debt principal | — | (3,333) | ||
| Payments of finance lease | — | (49) | ||
| Net cash provided by financing activities | 87,775 | 29,196 | ||
| Increase in cash, cash equivalents and restricted cash | 82,265 | 10,782 | ||
| Cash, cash equivalents and restricted cash, beginning of period | 57,073 | 46,291 | ||
| Cash, cash equivalents and restricted cash, end of period | $ | 139,338 | $ | 57,073 |
| Supplemental cash flow disclosure: | ||||
| Cash paid for interest | $ | — | $ | 62 |
| Supplemental disclosure of non-cash activities: | ||||
| Transfer of finance lease asset to property and equipment | $ | — | $ | 85 |
| Capital expenditures included in accounts payable or accrued expenses | $ | 443 | $ | — |
| Issuance costs included in accounts payable or accrued expenses | $ | 1,550 | $ | — |
| Reconciliation to amounts within the consolidated balance sheets: | ||||
| Cash and cash equivalents | $ | 137,531 | $ | 55,291 |
| Restricted cash | 1,807 | 1,782 | ||
| Cash, cash equivalents and restricted cash, end of period | $ | 139,338 | $ | 57,073 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.